The combined company will operate as œGyre Therapeutics, Inc. with its common stock traded on Nasdaq under trading symbol œGYRE effective Tuesday, October 31, 2023 SAN DIEGO, Oct. 30, 2023 (GLOBE...
Catalyst Clinical Research, a provider of specialized clinical development solutions, acquired Genpro Research, a Massachusetts-based global clinical research organization with staff in the US, India, and Ireland.
CARLSBAD, CA / ACCESSWIRE / March 27, 2023 / Catalyst Global, an international non-profit organization committed to increasing access to critical sexual and reproductive health (SRH) products and services in low- and middle-income countries, announced a new board member today, Dr. Jotham Musinguzi.
GC Biopharma Corp., provider of biopharmaceutical products in South Korea, has signed an asset purchase agreement with Catalyst Biosciences to acquire three programs related to the orphan hematology disorders.
Catalyst Biosciences Provides Corporate Update
YONGIN, South Korea, Feb. 27, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : CBIO) to acquire 3 programs related to the orphan hematology disorders.
Catalyst Receives FDA 510(k) Clearance for its Convertible Stemmed Total Shoulder Arthroplasty System
Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5...
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million.
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that JDS1, LLC, one of the Company’s stockholders, has dismissed its lawsuits against the Company.